The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2019
Filed:
Mar. 19, 2018
Applicant:
Synergy Pharmaceuticals, Inc., New York, NY (US);
Inventors:
Stephen Comiskey, Doylestown, PA (US);
Rong Feng, Langhorne, PA (US);
John Foss, Doylestown, PA (US);
Kunwar Shailubhai, Audubon, PA (US);
Assignee:
SYNERGY PHARMACEUTICALS, INC., New York, NY (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/10 (2006.01); C07K 7/54 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 38/12 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/501 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/765 (2006.01); A61K 31/78 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01); C07K 7/08 (2006.01); C07K 7/64 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/10 (2013.01); A61K 9/0053 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 9/1676 (2013.01); A61K 9/2054 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/192 (2013.01); A61K 31/501 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/765 (2013.01); A61K 31/78 (2013.01); A61K 38/12 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/38 (2013.01); C07K 7/08 (2013.01); C07K 7/54 (2013.01); C07K 7/64 (2013.01); C12Y 406/01002 (2013.01);
Abstract
The invention provides low-dose formulations of guanylate cyclase-C ('GCC') agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.